跳至主要内容
临床试验/NCT03489590
NCT03489590已完成早期 1 期

19F Magnetic Resonance Imaging to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis

University of North Carolina, Chapel Hill1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2015年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
入组人数
42
试验地点
1
主要终点
Obtain technically sufficient 19F MRI images

研究概览

简要总结

An open label non-randomized study enrolling up to 20 healthy participants and up to 30 participants with cystic fibrosis to establish a healthy versus disease comparison. Each participant will receive a mixture of inert gas (perfluoropropane (PFP)) in a ratio of 79% PFP to 21% oxygen as a contrast agent to enhance visualization of the airway and alveolar spaces using magnetic resonance imaging of inert gas/oxygen mixtures. The study consists of a screening visit followed by up to 2 study visits.

详细描述

The goal of this study is to evaluate the ability of conventional 'thermally' polarized perfluorinated gases (19F) mixed with oxygen to detect changes in ventilation using magnetic resonance imaging (MRI). A secondary goal is to assess the repeatability and the within-subject variability of these findings in CF lung disease. This is an open label pilot study expanding on work by other investigators currently using this technique in human subjects. Projection images using controlled breathing techniques will be obtained using 19F MRI, correlating spirometric variables with regional distribution of the gases.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

19F MRI with PFP

Experimental

PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet.

干预措施: PFP (Drug)

结局指标

主要结局

Obtain technically sufficient 19F MRI images

时间窗: 1 day

Determine if 19F gas images of the human lung and airways can be obtained in both single breath-hold and gated breathing imaging studies with adequate signal level and image contrast to extract regional lung ventilation information.

次要结局

  • Determine the reproducibility of ventilation assessments in the adult cystic fibrosis (CF) population.(1 week)
  • Compare quantitative and qualitative image measures of lung ventilation using 19F MRI imaging to spirometric values.(1 day)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset EpilepsyPartial Seizures With Secondary Generalization
NCT03417297University of North Carolina, Chapel Hill10
进行中(未招募)
不适用
Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in childre
EUCTR2006-004153-22-ATBayer Schering Pharma140
进行中(未招募)
不适用
Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in childreGadovist as diagnostic imaging agent is approved only for adult patients. Diseases usually representing indications for contrast-enhanced Magnetic Resonance Imaging (CE-MRI) are common also in a pediatric population. This study is a clinical routinely study in pediatric patients (male/ female) aged 2-17 years (3 age groups: 2-6, 7-11, and 12-17 years) who are scheduled to undergo Gd-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).MedDRA version: 9.1Level: PTClassification code 10029815Term: Nuclear magnetic resonance imaging
EUCTR2006-004153-22-SEBayer AB, Bayer Health Care, Bayer Schering Pharma140
进行中(未招募)
不适用
Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in childreGadovist as diagnostic imaging agent is approved only for adult patients. Diseases usually representing indications for contrast-enhanced Magnetic Resonance Imaging (CE-MRI) are common also in a pediatric population. This study is a clinical routinely study in pediatric patients (male/ female) aged 2-17 years (3 age groups: 2-6, 7-11, and 12-17 years) who are scheduled to undergo Gd-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).MedDRA version: 9.1Level: PTClassification code 10029815Term: Nuclear magnetic resonance imaging
EUCTR2006-004153-22-DEBayer Schering Pharma AG140
进行中(未招募)
不适用
Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in childreGadovist as diagnostic imaging agent is approved only for adult patients. Diseases usually representing indications for contrast-enhanced Magnetic Resonance Imaging (CE-MRI) are common also in a pediatric population. This study is a clinical routinely study in pediatric patients (male/ female) aged 2-17 years (3 age groups: 2-6, 7-11, and 12-17 years) who are scheduled to undergo Gd-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).MedDRA version: 9.1Level: PTClassification code 10029815Term: Nuclear magnetic resonance imaging
EUCTR2006-004153-22-DKBayer AB, Bayer Schering Pharma140